Mouse Anti-MAGEA4 Recombinant Antibody (CBT2391) (V2LY-0625-LY1799)

Freiberger, S. N., Holzmann, D., Morand, G. B., Hüllner, M., Levesque, M. P., Dummer, R., ... & Rupp, N. J. (2023). Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. Journal of Cancer Research and Clinical Oncology, 149(9), 5645-5653.

Connacher, R., Avraam, K., Ross, E., Schneck, M., Van Kerckhoven, M., Van Rossom, S., ... & Wang, T. (2023). 198 Development, validation and concordance of two MAGE-A4 immunohistochemistry (IHC) assays to establish prognostic value of MAGE-A4 expression in synovial sarcoma.

Fleming, M. C., Chiou, L. F., Tumbale, P. P., Droby, G. N., Lim, J., Norris-Drouin, J. L., ... & Bowers, A. A. (2022). Discovery and structural basis of the selectivity of potent cyclic peptide inhibitors of MAGE-A4. Journal of medicinal chemistry, 65(10), 7231-7245.

Hashimoto, K., Nishimura, S., Ito, T., Oka, N., Kakinoki, R., & Akagi, M. (2022). Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma. European Journal of Histochemistry: EJH, 66(3).

Davari, K., Holland, T., Prassmayer, L., Longinotti, G., Ganley, K. P., Pechilis, L. J., ... & Ellinger, C. (2021). Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. Journal for Immunotherapy of Cancer, 9(3).

Coles, C. H., McMurran, C., Lloyd, A., Hock, M., Hibbert, L., Raman, M. C., ... & Harper, S. (2020). T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. Journal of Biological Chemistry, 295(33), 11486-11494.

Ishihara, M., Kageyama, S., Miyahara, Y., Ishikawa, T., Ueda, S., Soga, N., ... & Shiku, H. (2020). MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC cancer, 20(1), 1-8.

Sanderson, J. P., Crowley, D. J., Wiedermann, G. E., Quinn, L. L., Crossland, K. L., Tunbridge, H. M., ... & Gerry, A. B. (2020). Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology, 9(1), 1682381.

Kakimoto, T., Matsumine, A., Kageyama, S., Asanuma, K., Matsubara, T., Nakamura, T., ... & Sudo, A. (2019). Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY‑ESO‑1 and MAGE‑A4 in high‑grade soft‑tissue sarcoma. Oncology Letters, 17(4), 3937-3943.

Van Tine, B. A., Butler, M. O., Araujo, D., Johnson, M. L., Clarke, J., Liebner, D., ... & Hong, D. S. (2019). ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma. Annals of Oncology, 30, v684-v685.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Antibody Pairs

MAGEA4 Matched Antibody Pair (704)

Related Products

Mouse Anti-MAGEA4 Recombinant Antibody (3D12)

MAGEA4 Matched Antibody Pair (704)

Mouse Anti-MAGEA4 Antibody (8BA20)

Mouse Anti-MAGEA4 Recombinant Antibody (CBT3266)

Mouse Anti-MAGEA4 Recombinant Antibody (CBFYM-1312)

Mouse Anti-MAGEA4 Antibody (8BA19)

Mouse Anti-MAGEA4 Recombinant Antibody (CBFYM-1311)

Isotype control